Charles River Laboratories International, Inc. - CRL STOCK NEWS

Charles River Laboratories (NYSE: CRL) has announced the opening of its High Quality (HQ) Plasmid DNA Centre of Excellence in Cheshire, UK, aiming to enhance plasmid DNA manufacturing for cell and gene therapy development. This 16,000 square foot facility will quadruple the company’s capacity to address global supply shortages and expedite the delivery of therapeutic materials. The expansion follows the acquisition of Cognate BioServices in March 2021.

Charles River Laboratories (NYSE: CRL) and Ziphius Vaccines announced a partnership to manufacture plasmid DNA, a key component for clinical-phase research. The collaboration aims to expedite the development of Ziphius' self-amplifying RNA technology, which promises enhanced protein expression at lower doses. This deal leverages Charles River's expertise in GMP plasmid production, beneficial for Ziphius’ clinical testing and vaccine development timelines. The partnership reflects a growing focus on advanced therapies, particularly in vaccine development.

Charles River Laboratories (NYSE: CRL) and ASC Therapeutics have expanded their partnership to manufacture ASC618, a second-generation gene therapy targeting hemophilia A. This collaboration leverages Charles River's expertise in Good Manufacturing Practice (GMP) for virus production established since 2019. ASC618 aims to deliver a modified version of the F8 gene to treat hemophilia A, following ASC Therapeutics' receipt of IND clearance and key regulatory designations in the U.S. and Europe. The partnership underscores a strong relationship built on trust and shared objectives for therapeutic development.

Charles River Laboratories (NYSE: CRL) will present at the Jefferies Healthcare Conference on June 8 at 10:00 a.m. ET, and at the William Blair 42nd Annual Growth Stock Conference on June 9 at 10:40 a.m. CT (11:40 a.m. ET). The presentations will cover the company's strategic focus and recent business developments. Live webcasts will be available on the Investor Relations section of the Charles River website, with replays accessible for two weeks after each event.

Charles River supports drug development for biotech and pharmaceutical sectors globally.

Charles River Laboratories (CRL) reported a strong performance for Q1 2022, with revenues reaching $913.9 million, marking a 10.8% increase year-over-year. Adjusted earnings per share (EPS) stood at $2.75, up 8.7% from the previous year. Key growth was driven by acquisitions (4.7% contribution) and organic growth of 9.4%. However, revenue was negatively impacted by foreign currency translation and divestitures. The company updated its 2022 guidance, raising reported revenue growth expectations to 13.5% - 15.5%.

Charles River Laboratories (NYSE: CRL) and Valo Health have launched Logica™, an AI-powered drug discovery solution that combines biological insights with optimized preclinical assets. This integrated offering leverages Valo's Opal Computational Platform and Charles River's expertise to streamline drug discovery. Logica features Advanceable Lead (Logica-AL™) and Candidate (Logica-C™) programs, targeting a 90% success rate in lead series and delivering development candidates 58% of the time. The collaboration marks a significant step forward in drug development, focusing on client value generation.

Charles River Laboratories (CRL) will release its first-quarter 2022 financial results on May 4, before market opening. A conference call to discuss these results is scheduled for the same day at 9:30 a.m. ET. Investors can access the live webcast through the Investor Relations section on CRL's website. The company offers key products and services aimed at accelerating research and drug development for pharmaceutical and biotech sectors.

Charles River Laboratories International, Inc. (NYSE: CRL) has published its 2021 Corporate Citizenship Report, highlighting ESG commitments and initiatives. The report emphasizes leadership accountability, employee engagement through global Resource Groups, community investments, and significant reductions in greenhouse gas emissions. Notably, the company aims for 100% renewable electricity across facilities by 2023. The report adheres to SASB and GRI standards, showcasing Charles River's dedication to corporate responsibility.

Charles River Laboratories (CRL) has acquired Explora BioLabs for approximately $295 million in cash, enhancing its Charles River Accelerator and Development Lab (CRADL™) footprint. This acquisition adds over 15 vivarium facilities across key biohubs like Southern California, San Francisco, and Boston, with plans for expansion in Seattle. Explora BioLabs had an annual revenue of $38 million in 2021, with expected strong growth. The acquisition is projected to be slightly accretive to non-GAAP earnings per share starting in 2023.